argenx announces results of Annual General Meeting 2017
(WorldNews Netherlands)

April 26, 2017 Breda, the Netherlands / Ghent, Belgium - argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company`s Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CEST. Voting results All proposed resolutions on the agenda for this annual meeting were approved. The results of the votes will be posted shortly on the Company`s website and are summarized below: approval of the conversion of the Company into a Societas Europaea, a European...